Targeted pharmacological therapy restores β-cell function for diabetes remission

Area of Science:

• * Endocrinology and Diabetes Research
• * Cellular Biology and Regenerative Medicine

Background:

• * Dedifferentiation of pancreatic beta cells is a key factor in beta cell dysfunction and diabetes.
• * Pharmacological strategies to target dedifferentiated beta cells for diabetes remission remain largely unexplored.

Purpose of the Study:

• * To investigate mechanisms of beta cell dedifferentiation and dysfunction in a mouse model of diabetes.
• * To identify and evaluate pharmacological interventions for targeting dedifferentiated beta cells to achieve diabetes remission.

Main Methods:

• * Streptozotocin-induced diabetes model in mice.
• * Single-cell RNA sequencing (scRNA-seq) of islets to identify markers of beta cell dedifferentiation.
• * Pharmacological treatments including insulin and a Glucagon-like peptide-1 (GLP-1)-estrogen conjugate.

Main Results:

• * scRNA-seq identified key markers and pathways linked to beta cell dedifferentiation and dysfunction.
• * Insulin treatment activated the insulin receptor pathway, restoring beta cell maturation and function.
• * GLP-1-estrogen conjugate significantly reduced insulin needs, enhanced beta cell survival and regeneration via ER-associated protein degradation, and protected human beta cells from cytokine-induced dysfunction.

Conclusions:

• * Beta cell dedifferentiation is a reversible process amenable to pharmacological intervention.
• * Insulin therapy and targeted delivery of estrogen via GLP-1 conjugates represent promising strategies for beta cell regeneration and diabetes remission.
• * This research uncovers novel therapeutic targets for addressing beta cell dysfunction in diabetes.